Study finds association between painkillers in pregnancy and male reproductive problems

Using mild painkillers in pregnancy appears to raise the risk of cryptorchidism (undescended testicles) in baby boys, new EU-funded research suggests. The findings offer an explanation of why cryptorchidism, which is the biggest risk factor for poor semen quality and testicular cancer in later life, is becoming more common.

The study is published online in the journal Human Reproduction. EU support for the work came from the DEER ('Developmental effects of environment on reproductive health') and CONTAMED ('Contaminant mixtures and human reproductive health - novel strategies for health impact and risk assessment of endocrine disrupters') projects, which each received EUR 3.5 million under the Environment Theme of the Seventh Framework Programme (FP7).

Rates of cryptorchidism are on the rise; in Denmark, just 1.8% of newborn boys were affected in 1959-1961, but by 1997-2001 that figure had risen to 8.5%. Studies in rats have suggested that cryptorchidism may be caused by a lack of male sex hormones during a particular period of pregnancy. So-called endocrine disruptors, molecules that interfere with or block the action of hormones, are thought to be behind the problem. However, tracking down these endocrine disruptors has proven difficult. Some studies have pointed to certain common painkillers, namely aspirin, paracetamol and ibruprofen, which may reduce testosterone production and could act as endocrine disruptors.

In this study, the scientists set out to study the influence of mild analgesics on male reproductive disorders in both humans and rats.

For the human part of the study, the scientists quizzed over 2,000 pregnant women in Denmark and Finland on their use of medication during pregnancy. The baby boys were examined at birth by paediatricians who looked for signs of cryptorchidism and graded any cases found according to their severity.

The results were clear; women who had used more than one kind of painkiller at the same time were seven times more likely to give birth to a son with some form of cryptorchidism than a woman who had not taken painkillers.

The second trimester appears to be a particularly sensitive time; taking any painkiller during this time more than doubled the risk of cryptorchidism, and taking more than one kind of painkiller during the second trimester increased the risk 16-fold.

Studies in rats confirmed that analgesics do indeed disrupt the production of androgens, resulting in a lack of testosterone during the period of pregnancy when the male sex organs are formed. According to the researchers, mild analgesics effectively halved testosterone levels in the testes of unborn rats.

The findings are important because around half of pregnant women in Europe and the US report taking mild painkillers, usually paracetamol.

"If exposure to endocrine disruptors is the mechanism behind the increasing reproductive problems among young men in the western world, this research suggests that particular attention should be paid to the use of mild analgesics during pregnancy, as this could be a major reason for the problems," commented Dr Henrik Leffers of the Rigshospitalet in Copenhagen, Denmark, who led the research.

"A single paracetamol tablet (500 mg) contains more endocrine disruptor potency than the combined exposure to the ten most prevalent of the currently known environmental endocrine disruptors during the whole pregnancy," Dr Leffers added.

"In fact, a single tablet will, for most women, be at least a doubling of the exposure to the known endocrine disruptors during the pregnancy and that dose comes on a single day, not spread out over nine months as with the environmental endocrine disruptors. Thus, for women using mild analgesics during the pregnancy, the mild analgesics will be by far the largest exposure to endocrine disruptors."

The team note that more research is needed into this issue; for their part, they will continue to monitor the boys born during the study, who are now entering puberty.

On the issue of whether pregnant women should take painkillers or not, Dr Leffers says: "As biologists this is not something we can advise women about. So we recommend that pregnant women seek advice from their physician before using mild analgesics and in general follow the advice to use as little medicine during pregnancy as possible."

For further information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...